Years after the first US biosim launches, doctors still have their concerns: survey

Years after the first US biosim launches, doctors still have their concerns: survey

Source: 
Fierce Pharma
snippet: 

AbbVie’s mega-blockbuster Humira is finally subject to biosimilar competition in the United States. With the launch last month of Amgen’s Amjevita—to be followed later this year by other Humira biosimilars entering the market—patients finally have access to lower-cost alternatives to the immunology blockbuster.